A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors
Latest Information Update: 25 Oct 2024
At a glance
- Drugs TQB 2252 (Primary)
 - Indications Solid tumours
 - Focus Adverse reactions
 - Sponsors Chia Tai Tianqing Pharmaceutical Group
 
Most Recent Events
- 25 Oct 2024 New trial record